Saturday, July 11, 2026

Drug profile · INN

regdanvimab

regdanvimab (REGKIRONA) is a spike glycoprotein inhibitor.

EMA: withdrawn Antiinfectives for systemic use (J06) J06BD06
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — regdanvimab
Class
Antiinfectives for systemic use (J06)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

regdanvimab (REGKIRONA) is a spike glycoprotein inhibitor.

Key facts

INN regdanvimab
Brand REGKIRONA
Mechanism Spike glycoprotein inhibitor
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BD06

Mechanism of action

Spike glycoprotein inhibitor

Primary target: Spike glycoprotein

Approval history

Authority Status Date
EMA withdrawn

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is regdanvimab?

regdanvimab (REGKIRONA) is a spike glycoprotein inhibitor.

What is the brand name for regdanvimab?

REGKIRONA is a marketed brand name for regdanvimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.